Volume 5, Issue 6, November 2017, Page: 78-80
Ovarian Hyperstimulation Syndrome Due to Exogenous Human Chorionic Gonadotropin (hCG) Presenting More Than 7 Days After hCG Administration
Masaki Kobayashi, Department of Obstetrics and Gynecology, Osaka University, Suita City, Osaka, Japan
Keiichi Kumasawa, Department of Obstetrics and Gynecology, Osaka University, Suita City, Osaka, Japan
Kaori Koizumi, Department of Obstetrics and Gynecology, Osaka University, Suita City, Osaka, Japan
Tsuyoshi Takiuchi, Department of Obstetrics and Gynecology, Osaka University, Suita City, Osaka, Japan
Hitomi Nakamura, Department of Obstetrics and Gynecology, Osaka University, Suita City, Osaka, Japan
Kenjiro Sawada, Department of Obstetrics and Gynecology, Osaka University, Suita City, Osaka, Japan
Tadashi Kimura, Department of Obstetrics and Gynecology, Osaka University, Suita City, Osaka, Japan
Received: Dec. 6, 2017;       Accepted: Dec. 23, 2017;       Published: Jan. 15, 2018
DOI: 10.11648/j.jgo.20170506.12      View  1852      Downloads  108
Abstract
We present a case of ovarian hyperstimulation syndrome (OHSS) occurring 8 days after human chorionic gonadotropin (hCG) administration. OHSS is classified as late type if it occurs 12 to 17 days after hCG administration and early type if it occurs within 7 days. Thus, the condition in this patient did not fit the definition of early or late OHSS. The OHSS was mild, and she recovered in approximately 10 days without requiring admission. The patient was not pregnant, and the OHSS was shown to be induced by exogenous hCG administration not endogenous hCG. In conclusion, OHSS can occur 8 to 11 days after hCG administration and it is important to distinguish whether OHSS is induced by endogenous or exogenous hCG.
Keywords
Ovarian Hyperstimulation Syndrome, Chorionic Gonadotropin, Ovarian Cysts, Clomiphene, Infertility
To cite this article
Masaki Kobayashi, Keiichi Kumasawa, Kaori Koizumi, Tsuyoshi Takiuchi, Hitomi Nakamura, Kenjiro Sawada, Tadashi Kimura, Ovarian Hyperstimulation Syndrome Due to Exogenous Human Chorionic Gonadotropin (hCG) Presenting More Than 7 Days After hCG Administration, Journal of Gynecology and Obstetrics. Vol. 5, No. 6, 2017, pp. 78-80. doi: 10.11648/j.jgo.20170506.12
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Pereira N, Lekovich JP, Kligman I, et al. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney. Gynecol Endocrinol 2017; 33: 593-597.
[2]
Keiser UB. The Pathogenesis of the Ovarian Hyperstimulation Syndrome. N Engl J Med 2003; 349: 729-732.
[3]
Dahl Lyons CA, Wheeler CA, Frishman GN, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994; 9: 792-799.
[4]
Al-Shawaf T, Grudzinskas JG. Prevention and treatment of ovarian hyperstimulation syndrome. Best Prac Res Clinical Obstet Gynaecol 2003; 17: 249-261.
[5]
Lee KH, Kim SH, Jee BC, et al. Comparison of clinical characteristics between early and late patterns in hospitalized patients with ovarian hyperstimulation syndrome. Fertil Steril 2010; 93: 2274-2280.
[6]
Mathur RS, Akande AV, Keay SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 901-907.
[7]
Korhonen K, Savolainen-Peltonen H, Mikkola T, et al. C-reactive protein response is higher in early than in late ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 2016; 207: 162-168.
[8]
Papanikolaou EG, Tournaye H, Verpoest W, et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 2005; 20: 636-641.
[9]
Elena P, Isabel AM, Raul G, et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod 2006; 21: 1453–1460.
[10]
Alper MM, Smith LP, Sills ES. Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management. J Exp Clin Assist Reprod 2009; 6: 3.
[11]
Jellad S, Haj HA, Basly M, et al. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. J Gynecol Obstet Hum Reprod 2017; 46: 87-91.
Browse journals by subject